Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Finazzi

Showing results (121-130 of 132) with videos related to

Pageof 14
Sort By:
Leukemia|January 26, 2007
A unified definition of clinical resistance/intolerance to hydroxyurea in essential thrombocythemia: results of a consensus process by an international working groupG Barosi, C Besses, G Birgegard, et al.
Human Mutation|January 1, 1996
Two novel (R(-11)C; T394D) and two repeat missense mutations in the protein C gene associated with venous thrombosis in six kindredsH A Ireland, M D Boisclair, J Taylor, et al.
Leukemia|September 20, 2011
Incidence and risk factors for bleeding in 1104 patients with essential thrombocythemia or prefibrotic myelofibrosis diagnosed according to the 2008 WHO criteriaG Finazzi, A Carobbio, J Thiele, et al.
The American Journal of Medicine|May 1, 1996
Natural history and risk factors for thrombosis in 360 patients with antiphospholipid antibodies: a four-year prospective study from the Italian RegistryG Finazzi, V Brancaccio, M Moia, et al.
Blood Cancer Journal|December 1, 2015
Practice-relevant revision of IPSET-thrombosis based on 1019 patients with WHO-defined essential thrombocythemiaT Barbui, A M Vannucchi, V Buxhofer-Ausch, et al.
Blood Cancer Journal|March 9, 2013
Mutations with epigenetic effects in myeloproliferative neoplasms and recent progress in treatment: Proceedings from the 5th International Post-ASH SymposiumA Tefferi, O Abdel-Wahab, F Cervantes, et al.
Deutsche Medizinische Wochenschrift (1946)|October 21, 2006
[Clinical research at the European LeukemiaNet]S Saussele, K Adam, A Hochhaus, et al.
Leukemia|June 7, 2013
Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international studyA Tefferi, E Rumi, G Finazzi, et al.
Leukemia|August 26, 2014
Clinical end points for drug treatment trials in BCR-ABL1-negative classic myeloproliferative neoplasms: consensus statements from European LeukemiaNET (ELN) and Internation Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT)G Barosi, A Tefferi, C Besses, et al.
The Netherlands Journal of Medicine|March 18, 1999
Diagnosis, pathogenesis and treatment of the myeloproliferative disorders essential thrombocythemia, polycythemia vera and essential megakaryocytic granulocytic metaplasia and myelofibrosisJ J Michiels, J Kutti, P Stark, et al.
Pageof 14

Showing results (121-130 of 132) with videos related to

Sort By:
Pageof 14
Leukemia|January 26, 2007
A unified definition of clinical resistance/intolerance to hydroxyurea in essential thrombocythemia: results of a consensus process by an international working groupG Barosi, C Besses, G Birgegard, et al.
Human Mutation|January 1, 1996
Two novel (R(-11)C; T394D) and two repeat missense mutations in the protein C gene associated with venous thrombosis in six kindredsH A Ireland, M D Boisclair, J Taylor, et al.
Leukemia|September 20, 2011
Incidence and risk factors for bleeding in 1104 patients with essential thrombocythemia or prefibrotic myelofibrosis diagnosed according to the 2008 WHO criteriaG Finazzi, A Carobbio, J Thiele, et al.
The American Journal of Medicine|May 1, 1996
Natural history and risk factors for thrombosis in 360 patients with antiphospholipid antibodies: a four-year prospective study from the Italian RegistryG Finazzi, V Brancaccio, M Moia, et al.
Blood Cancer Journal|December 1, 2015
Practice-relevant revision of IPSET-thrombosis based on 1019 patients with WHO-defined essential thrombocythemiaT Barbui, A M Vannucchi, V Buxhofer-Ausch, et al.
Blood Cancer Journal|March 9, 2013
Mutations with epigenetic effects in myeloproliferative neoplasms and recent progress in treatment: Proceedings from the 5th International Post-ASH SymposiumA Tefferi, O Abdel-Wahab, F Cervantes, et al.
Deutsche Medizinische Wochenschrift (1946)|October 21, 2006
[Clinical research at the European LeukemiaNet]S Saussele, K Adam, A Hochhaus, et al.
Leukemia|June 7, 2013
Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international studyA Tefferi, E Rumi, G Finazzi, et al.
Leukemia|August 26, 2014
Clinical end points for drug treatment trials in BCR-ABL1-negative classic myeloproliferative neoplasms: consensus statements from European LeukemiaNET (ELN) and Internation Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT)G Barosi, A Tefferi, C Besses, et al.
The Netherlands Journal of Medicine|March 18, 1999
Diagnosis, pathogenesis and treatment of the myeloproliferative disorders essential thrombocythemia, polycythemia vera and essential megakaryocytic granulocytic metaplasia and myelofibrosisJ J Michiels, J Kutti, P Stark, et al.
Pageof 14